FDA clears Philip Morris to market 20 Zyn nicotine pouch variants as less harmful than cigarettes
The U.S. Food and Drug Administration has cleared Philip Morris to market its Zyn nicotine pouches as less harmful than cigarettes, covering 20 product variants. The authorization permits the company to claim that using Zyn instead of cigarettes lowers risks including mouth cancer, heart disease, lung cancer, stroke, emphysema and chronic bronchitis. The decision provides a strong regulatory endorsement as nicotine pouches become the fastest-growing nicotine product in the U.S. The development was first reported by Axios.